Navigation Links
Sales of Revlimid and the Launch of Several Premium-Priced Emerging Therapies Will Drive Robust 7.2 Percent Annual Growth in the Multiple Myeloma Drug Market
Date:12/6/2010

BURLINGTON, Mass., Dec. 6, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of Celgene's Revlimid in the first-line setting and the launch of several premium-priced emerging therapies will drive robust 7.2 percent annual growth through 2019 in the multiple myeloma drug market.

The Pharmacor 2010 findings from the topic entitled Multiple Myeloma which will publish later this month reveal that although the first-line setting is currently dominated by Takeda/Janssen-Cilag/Janssen's Velcade in terms of patient and market share, sales of Velcade will be rapidly eclipsed by the dramatic growth of Revlimid. The findings also reveal that sales of Celgene's Thalidomide/Thalomid and Fujimoto Seiyaku's Thaled will be more aggressively eroded compared with Velcade, owing to the approval of Revlimid in the first-line setting.

Sales of both Revlimid and Velcade will also increase in the relapsed/refractory setting, despite the entrance of novel emerging therapies such as Celgene's pomalidomide and Onyx Pharmaceuticals/Ono Pharmaceutical's carfilzomib. Revlimid will be used in combination with carfilzomib, while Velcade will experience increased uptake in the relapsed/refractory setting in combination with other emerging agents such as Keryx Biopharmaceuticals/AEterna Zentaris's perifosine, Merck's Zolinza and Novartis's panobinostat.

"The most commercially promising emerging therapies in development -- pomalidomide and carfilzomib -- belong to the same drug classes as the highly successful currently available therapies, but these two agents will struggle to attain the same market share as well-established agents," said Decision Resources Analyst Andrew Merron, Ph.D. "Other promising emerging agents such as perifosine, Zolinza and panobinostat will introduce novel mechanisms of action into the myeloma treatment paradigm."  

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
2. RF Technologies® Names Paul Reynard Senior Vice President-Sales and Service
3. Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion
4. Decline in Pharmaceutical Sales in The Cape Coral, Fla. Market Due to High Uninsurance Rates and Generic Utilization Will Be Offset by the Establishment of High-Risk Pool and Medical Homes
5. Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations
6. Yondelis(R) Sales Expanded by 70 Percent
7. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
8. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
9. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
10. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
(Date:4/26/2016)... 26, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... Hagerman , Pharm D., to Vice President of Education ... Diplomat, Hagerman will continue to lead and oversee Diplomat ... custom education and training to Diplomat employees and external ... Diplomat University also houses the quality assurance department, which ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by ... and deal with these stressors is to adopt a more healthful diet, but too ... Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... ... 29, 2016 , ... Coast Dental Fort Stewart is celebrating its grand opening ... the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be ... attendees will have the opportunity to meet general dentists Thomas Richards, DDS, and Josh ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification ... pleased to announce the launch of the GFCP Scoop in response ... The purpose of the GFCP Scoop site is to keep the ...
Breaking Medicine News(10 mins):